4//SEC Filing
Claiborne Cary J 4
Accession 0001213900-22-057513
CIK 0001513525other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 7:11 PM ET
Size
7.2 KB
Accession
0001213900-22-057513
Insider Transaction Report
Form 4
Claiborne Cary J
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2022-09-19$0.43/sh+25,000$10,735→ 1,025,000 total - Award
Common Stock
2022-09-20$0.42/sh+75,000$31,515→ 1,100,000 total
Footnotes (2)
- [F1]The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4196 through $0.4573, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4079 through $0.4230, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
ADIAL PHARMACEUTICALS, INC.
CIK 0001513525
Entity typeother
Related Parties
1- filerCIK 0001370930
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 7:11 PM ET
- Size
- 7.2 KB